These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17631180)

  • 21. [Anemia impact on treatments of cervical carcinomas].
    Marchal C; Rangeard L; Brunaud C
    Cancer Radiother; 2005 Mar; 9(2):87-95. PubMed ID: 15820436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
    Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A
    Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines.
    Djulbegovic B
    Best Pract Res Clin Haematol; 2005; 18(3):455-66. PubMed ID: 15792920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review.
    Bohlius JF; Langensiepen S; Engert A; Schwarzer G; Bennett CL
    Best Pract Res Clin Haematol; 2005; 18(3):449-54. PubMed ID: 15792919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anemia and chemotherapy].
    Ray-Coquard I; Bachelot T; Sebban C; Biron P; Guastalla JP; Blay JY
    Bull Cancer; 2003 Apr; 90 Spec No():S133-43. PubMed ID: 12856425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
    Macdougall IC
    Curr Hematol Rep; 2005 Nov; 4(6):436-40. PubMed ID: 16232379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of recombinant hematopoietins on blood-loss anemia in mice.
    Jones KB; Anderson DW; Longmore GD
    Iowa Orthop J; 2005; 25():129-34. PubMed ID: 16089085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.
    Ludwig H; Aapro M; Bokemeyer C; Macdonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
    Eur J Cancer; 2009 Jun; 45(9):1603-15. PubMed ID: 19278851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
    Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
    Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoietin in clinical practice: current use, effect on survival, and future directions.
    Oster HS; Hoffman M; Prutchi-Sagiv S; Katz O; Neumann D; Mittelman M
    Isr Med Assoc J; 2006 Oct; 8(10):703-6. PubMed ID: 17125118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of cancer-related anemia.
    Badzek S; Curić Z; Krajina Z; Plestina S; Golubić-Cepulić B; Radman I
    Coll Antropol; 2008 Jun; 32(2):615-22. PubMed ID: 18756919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anemia in patients with cancer].
    Kobune M; Kato J; Niitsu Y
    Nihon Rinsho; 2008 Mar; 66(3):524-9. PubMed ID: 18330028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombotic complications of erythropoiesis-stimulating agents.
    Lippi G; Franchini M; Favaloro EJ
    Semin Thromb Hemost; 2010 Jul; 36(5):537-49. PubMed ID: 20632251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
    Bohlius J; Tonia T; Schwarzer G
    Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy.
    Krzakowski M;
    Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):705-13. PubMed ID: 18691854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of recombinant erythropoietin in childhood cancer.
    Shankar AG
    Oncologist; 2008 Feb; 13(2):157-66. PubMed ID: 18305061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anemia management in oncology and hematology.
    Spivak JL; Gascón P; Ludwig H
    Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.